Pharmaceutical composition of phenol derivative with improved stability and its use
A pharmaceutical composition with benbitimod and specific additives addresses stability and safety issues in dermatitis treatments, offering improved efficacy and reduced symptom recurrence.
Patent Information
- Application Number
- JP2026525285
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-02
- Filing Date
- 2024-10-30
- Publication Date
- 2026-11-09
AI Technical Summary
Current treatments for atopic dermatitis and seborrheic dermatitis, particularly in pediatric patients, face challenges with stability, safety, efficacy, and uniformity of pharmaceutical compositions, often leading to recurrence of symptoms and adverse effects from hormonal drugs.
A pharmaceutical composition comprising a phenol derivative (benbitimod) as the active ingredient, combined with specific emulsifiers, thickeners, humectants, chelating agents, and pH adjusters, formulated as uniform emulsion droplets less than 10 μm in diameter, ensuring stability and safety.
The composition provides a stable, safe, and effective treatment for atopic and seborrheic dermatitis, particularly in children, with improved uniformity and reduced recurrence of symptoms.
Smart Images

Figure 2026537452000001_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present disclosure belongs to the field of pharmaceutical compositions, and specifically relates to a pharmaceutical composition of a phenol derivative with improved stability and use thereof. BACKGROUND ART
[0002] Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease. In recent years, the incidence of AD has been on a continuous rise worldwide. The etiology and pathogenesis of AD remain unclear, and it may be related to multiple factors such as heredity, skin barrier defects, immunity, environment, and microbial colonization. At present, the treatment of mild to moderate pediatric AD is usually dominated by topical glucocorticoids and calcineurin inhibitors. Among them, the treatment of severe or refractory pediatric AD is highly difficult and requires individualized therapy. Without systematic and universal pharmaceutical treatment, the quality of life and psychological health of affected children will be seriously adversely affected.
[0003] Seborrheic dermatitis (SD) is a chronic, papular, scaly, superficial inflammatory skin disease that occurs in areas of sebum secretion. Typical lesions are dark red or yellowish-red patches formed by the fusion of follicular papules, accompanied by oily scales or crusts and varying degrees of itching. SD is a chronic, recurrent inflammatory skin disease that usually presents as red, scaly lesions. It has a prevalence of 5% in healthy individuals, with 70.3% occurring on the scalp. It is most common in infants, adolescents, and adults. Seborrheic dermatitis refers to a disease of the scalp, and it differs from simple dandruff in that it presents with erythema as a sign of inflammation, greater degree of scalp shedding, and may be accompanied by itching and burning, as well as eczema on other parts of the body. The disease can occur in the form of plaques, but can also affect the entire scalp, often extending beyond the hairline, and frequently including the forehead, around the neck, and both ears. In severe cases, secondary infections of the scalp may occur, and the changes may manifest as a spongy texture, forming blisters and scabs, and potentially oozing fluid. Seborrheic dermatitis also commonly occurs in infancy and usually resolves spontaneously between 8 and 12 months of age. Scalp changes in infants include occasional appearances of erythema, scalp peeling, blisters, and scabs. These changes may resolve spontaneously within a few weeks, recur intermittently, or persist throughout childhood. These changes are usually accompanied by similar lesions around the eyelids, nose, and both ears. Subsequently, the condition frequently occurs after adolescence and can persist for life, potentially becoming more severe. Approximately 1-3% of people are affected by this disease. The etiology and pathogenesis of SD are still unknown, but the complex interaction of Malassezia fungi, keratinocytes, and immune responses plays a crucial role in the development of SD. Seborrheic dermatitis and inflammatory skin diseases such as atopic dermatitis share some of the same pathogenic factors, such as the regulatory control of factors that stimulate the proliferation and differentiation of keratinocytes, and the disruption of the skin barrier. Atopic dermatitis usually manifests as a Th2 immune response, with elevated levels of interleukin (IL)-4 and IL-13, while seborrheic dermatitis mainly manifests as a Th2 and Th17 response, with elevated levels of IL-4, IL-17, and IL-8.
[0004] Currently, treatment for seborrheic dermatitis involves combining simple anti-inflammatory drugs (e.g., topical hormone preparations, calcineurin inhibitors) with moisturizing skincare products, but the effectiveness rate is low, and symptoms tend to recur when the medication is discontinued.
[0005] In CN108066279A and CN113797159A, we disclosed our findings on a benbitimod topical cream formulation, but the properties of the samples were unfavorable, still containing a large proportion of lumpy oily material, which affected product performance. Furthermore, in the example in CN114042041A, it was found that the white petrolatum in the formulation caused the formation of a waxy substance, and even formulations containing low levels of white petrolatum caused unevenness in the emulsion, while formulations without petrolatum oil produced a uniform emulsion.
[0006] Therefore, providing pharmaceutical compositions / formulations for treating pediatric Alzheimer's disease (AD) and Stabilized Disease (SD) that alleviate the anxiety and fear that hormonal drugs cause in children, while also ensuring safety, stability, efficacy, and uniformity of morphological characteristics, remains an urgent technical problem in this field. [Overview of the Initiative] [Means for solving the problem]
[0007] To improve the above technical problems, this disclosure provides: A pharmaceutical composition comprising an active ingredient selected from at least one compound shown in formula (I) and its pharmaceutically acceptable salts, a thickener, an emulsifier, a humectant, a chelating agent, a pH adjuster, an oil phase matrix, and water, [ka] To provide a pharmaceutical composition.
[0008] According to embodiments of this disclosure, the compound represented by formula (I) may be an E isomer or a Z isomer, and is preferably an E isomer represented by the following formula (I-1). [ka]
[0009] According to preferred embodiments of this disclosure, the compound represented by formula (I-1) is benbitimod.
[0010] According to embodiments of the present disclosure, the pharmaceutically acceptable salt may be selected from addition salts of the compound of formula (I) and a base.
[0011] In a preferred embodiment, the pharmaceutical composition preferably contains only the compound shown in formula (I) as the active ingredient, and more preferably only the E isomer shown in formula (I-1) (i.e., benbitimod) as the active ingredient.
[0012] According to embodiments of the present disclosure, in the pharmaceutical composition, the active ingredient exists as an emulsion droplet, and the diameter of the emulsion droplet is preferably less than 10 μm, for example, less than 5 μm.
[0013] According to embodiments of the present disclosure, in the pharmaceutical composition, the amount of the active ingredient by weight is 0.1 to 8 parts, for example, 0.5 to 5 parts, and exemplary amounts are 0.5 parts, 0.75 parts, 1 part, 1.25 parts, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, or 4 parts.
[0014] According to embodiments of the present disclosure, the thickening agent is one or more selected from hexadecanol, octadecanol, and cetostearyl alcohol.
[0015] According to embodiments of the present disclosure, in the pharmaceutical composition, the amount of the thickener is 2 to 15 parts by weight, for example, 5 to 10 parts, and exemplary, 6, 7, or 8 parts.
[0016] According to embodiments of the present disclosure, the emulsifier is one or more selected from macrogol cetostearyl ether, monobisstearate glyceryl, polyethylene glycol stearate (e.g., PEG-7 stearate), polyoxyethylene hydrogenated castor oil (polyoxyethylene (54) hydrogenated castor oil), and polysorbate 80. In some embodiments, the emulsifier is macrogol cetostearyl ether, monobisstearate glyceryl, and polysorbate 80; in other embodiments, the emulsifier is macrogol cetostearyl ether and monobisstearate glyceryl; and in further embodiments, the emulsifier is PEG-7 stearate and polysorbate 80. Preferably, the emulsifier comprises at least macrogol cetostearyl ether and monobisstearate glyceryl, for example, the emulsifier consists of macrogol cetostearyl ether and monobisstearate glyceryl, or macrogol cetostearyl ether, monobisstearate glyceryl, and polysorbate 80.
[0017] According to embodiments of the present disclosure, in the pharmaceutical composition, the amount of the emulsifier is 2 to 25 parts by weight, for example, 5 to 20 parts, and exemplary, 6, 6.5, 7, 7.5, 8, 10, 12, or 16 parts.
[0018] According to embodiments of the present disclosure, if the pharmaceutical composition contains two emulsifiers, the weight ratio of the two emulsifiers may be (1-3):(3-1), for example (1-2):(2-1), for example (1-1.5):(1.5-1), or for example (1-1.2):(1.2-1), with specific examples being 3:3.5, 3.5:3, or 1:1. Exemplarily, if the emulsifiers are macrogol cetostearyl ether and monobisstearate glyceryl, the weight ratio of macrogol cetostearyl ether to monobisstearate glyceryl may be (1-3):(3-1), for example (1-2):(2-1), for example (1-1.5):(1.5-1), or for example (1-1.2):(1.2-1), with specific examples being 3:3.5, 3.5:3, or 1:1.
[0019] According to embodiments of the present disclosure, in the pharmaceutical composition, if there are three types of emulsifiers, the proportion of each emulsifier in the total weight of the emulsifiers can be independently selected from 1 / 5 to 1 / 2, for example, 1 / 4 to 1 / 3, or for example, 2 / 7 to 1 / 3.
[0020] In some embodiments, when there are three types of emulsifiers, the weight ratio of the three emulsifiers may be (1.5~3):(1.5~3):1, for example (1.7~2.5):(1.7~2.5):1, and exemplary 3.5:3:1.5. For example, the emulsifiers consist of macrogol cetostearyl ether, monobisstearate glyceryl, and polysorbate 80, and the weight ratio of macrogol cetostearyl ether, monobisstearate glyceryl, and polysorbate 80 may be (1.5~3):(1.5~3):1, for example (1.7~2.5):(1.7~2.5):1, and exemplary 3.5:3:1.5.
[0021] According to embodiments of this disclosure, the humectant is one or more selected from propylene glycol, glycerin, polyethylene glycol, etc., and is preferably propylene glycol.
[0022] According to an embodiment of the present disclosure, in the pharmaceutical composition, the weight part of the humectant is 3 to 15 parts, for example, 5 to 12 parts, illustratively 6 parts, 7 parts, 8 parts, 9 parts or 10 parts.
[0023] According to an embodiment of the present disclosure, the chelating agent is one or more selected from the metal ion chelating agents of ethylenediaminetetraacetic acid, sodium gluconate, nitrilotriacetic acid, tartaric acid, citric acid and salts thereof, preferably, the salt is a sodium salt, a potassium salt or an ammonium salt. In some embodiments, the chelating agent is selected from ethylenediaminetetraacetic acid disodium salt (also called disodium edetate).
[0024] According to an embodiment of the present disclosure, in the pharmaceutical composition, the weight part of the chelating agent is 0.01 to 1 part, for example, 0.05 to 0.5 parts, illustratively 0.05 parts, 0.1 parts, 0.2 parts or 0.5 parts.
[0025] According to an embodiment of the present disclosure, the pH adjusting agent is selected from pH buffers, preferably a pH buffer of an organic acid and / or a salt thereof, for example, one or more selected from citric acid / sodium citrate buffer, tartrate buffer, malic acid buffer, acetic acid / sodium acetate buffer, and is preferably a citric acid / sodium citrate buffer.
[0026] According to an embodiment of the present disclosure, the oil phase matrix may comprise one or more selected from petrolatum, medium-chain triglycerides and paraffin, for example, the oil phase matrix comprises one or two of petrolatum and medium-chain triglycerides. The petrolatum is preferably white petrolatum. Preferably, the oil phase matrix comprises petrolatum and one or two optionally selected from medium-chain triglycerides and paraffin, more preferably, the oil phase matrix is petrolatum and medium-chain triglycerides.
[0027] According to embodiments of the present disclosure, in the pharmaceutical composition, the total weight of the oil phase matrix is 5 to 25 parts, for example, 8 to 20 parts, and exemplary 9, 10, 12, 13, 14, 15, 16, or 17 parts.
[0028] According to embodiments of the present disclosure, in the pharmaceutical composition, the amount of petrolatum (preferably white petrolatum) is 1 to 9 parts by weight, for example, 1 to 8 parts, 1 to 7 parts or 1 to 6 parts, for example, 1 to 5 parts, 2 to 6 parts, 3 to 6 parts or 4 to 6 parts, exemplary, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts or 6 parts, or greater than 1 part, greater than 1.5 parts, greater than 2 parts, greater than 2.5 parts, greater than 3 parts, greater than 3.5 parts, greater than 4 parts, greater than 4.5 parts, greater than 5 parts, greater than 5.5 parts or greater than 6 parts.
[0029] According to embodiments of this disclosure, the water is preferably purified water.
[0030] According to embodiments of the present disclosure, in the pharmaceutical composition, the amount of water by weight is 40 to 70 parts, for example, 45 to 60 parts or 50 to 65 parts, for example, 45 parts, 46 parts, 47 parts, 48 parts, 49 parts, 50 parts, 55 parts, 56 parts, 57 parts, 58 parts, 59 parts, 60 parts, 61 parts, 62 parts, 63 parts, 64 parts or 65 parts.
[0031] According to embodiments of the present disclosure, the pharmaceutical composition may further comprise an antioxidant, a preservative, and / or a penetration enhancer.
[0032] According to embodiments of this disclosure, the antioxidant is one or more selected from propyl gallate and dibutylhydroxytoluene (BHT), and preferably the antioxidant is dibutylhydroxytoluene.
[0033] According to embodiments of the present disclosure, in the pharmaceutical composition, the amount of the antioxidant by weight is 0.01 to 0.2 parts, for example, 0.05 to 0.15 parts, and exemplary, 0.05 parts, 0.1 parts, or 0.12 parts.
[0034] According to embodiments of this disclosure, the preservative is one or more selected from methylparaben, ethylparaben, and propylparaben, and is preferably ethylparaben.
[0035] According to embodiments of the present disclosure, in the pharmaceutical composition, the amount of the preservative by weight is 0.01 to 0.3 parts, for example, 0.05 to 0.15 parts, and exemplary, 0.1, 0.1, 0.15, or 0.2 parts.
[0036] According to embodiments of the present disclosure, the penetration enhancer is one or more selected from diethylene glycol monoethyl ether, isopropyl myristate, isopropyl palmitate, menthol, polyethylene glycol glyceryl caprylate, N-methylpyrrolidone, propylene carbonate, and isosorbide dimethyl ether, and is preferably diethylene glycol monoethyl ether.
[0037] According to embodiments of the present disclosure, in the pharmaceutical composition, the amount of the penetration enhancer is 0.1 to 5 parts by weight, for example, 0.5 to 3 parts, and exemplary, 1, 2, 3, or 4 parts.
[0038] According to embodiments of the present disclosure, the pH of the pharmaceutical composition is 4 to 6.5, for example, 4.5, 5, 5.2, 5.5, or 6.
[0039] In some embodiments, the above-mentioned humectant and penetration enhancer also serve as solvents for preparing the oil phase.
[0040] According to embodiments of this disclosure, the pharmaceutical composition comprises, by weight, 0.1 to 8 parts of an active ingredient, 2 to 15 parts of a thickener, 2 to 25 parts of an emulsifier, 3 to 15 parts of a humectant, 0.01 to 1 part of a chelating agent, 0.01 to 0.2 parts of an antioxidant, 0.01 to 0.3 parts of a preservative, 0 to 5 parts of a penetration enhancer, 5 to 25 parts of an oil phase matrix, 40 to 65 parts of water, and an appropriate amount of a pH adjuster. The active ingredient is the compound shown in formula (I), and it is preferable to use the E isomer shown in formula (I-1) as the active ingredient. Preferably, the thickening agent is octadecanol or cetostearyl alcohol. Preferably, the emulsifier is one selected from a combination of macrogol cetostearyl ether, monobisstearate glyceryl and polysorbate 80, a combination of macrogol cetostearyl ether and monobisstearate glyceryl, or a combination of PEG-7 stearate and polysorbate 80. Preferably, the humectant is selected from propylene glycol. Preferably, the chelating agent is selected from disodium ethylenediaminetetraacetate. Preferably, the oil phase matrix is one, two, or three selected from petrolatum, medium-chain triglycerides, and paraffin, and is preferably white petrolatum and medium-chain triglycerides. Preferably, the pH adjusting agent is selected from citrate / sodium citrate buffer or acetic acid / sodium acetate buffer. Preferably, the antioxidant is selected from dibutylhydroxytoluene. Preferably, the preservative is ethylparaben. Preferably, the penetration enhancer is diethylene glycol monoethyl ether. Preferably, the pH of the pharmaceutical composition is 4 to 6.5. Preferably, in each embodiment of the pharmaceutical composition, the sum of the parts by weight of each component of the pharmaceutical composition is 100 parts.
[0041] In some embodiments, the pharmaceutical composition is, in parts by weight, The compound comprises 0.5 to 5 parts of the E isomer of the compound shown in formula (I), 5 to 10 parts of cetostearyl alcohol, 5 to 20 parts of emulsifier, 5 to 12 parts of propylene glycol, 0.05 to 0.5 parts of chelating agent, 0.01 to 0.2 parts of antioxidant, 0.01 to 0.3 parts of preservative, 0 to 5 parts of penetration enhancer, 8 to 20 parts of oil phase matrix, 40 to 65 parts of water, and an appropriate amount of pH adjuster. Preferably, the emulsifier consists of macrogol cetostearyl ether, monobisstearate glyceryl, and polysorbate 80 in a weight ratio of (1.5-3):(1.5-3):1. Preferably, the oil phase matrix consists of white petrolatum and medium-chain triglycerides, with the amount of white petrolatum being 1 to 9 parts.
[0042] In some embodiments, the pharmaceutical composition is selected from any of the following formulations in parts by weight.
[0043] Formula 1: 1 part E isomer of the compound shown in formula (I), 2 parts white petrolatum, 7 parts cetostearyl alcohol, 3.5 parts macrogol cetostearyl ether, 10 parts medium-chain triglycerides, 3 parts monobisstearate glyceryl, 0.1 part dibutylhydroxytoluene, 0.15 parts ethylparaben, 1.5 parts polysorbate 80, 10 parts propylene glycol, 0.05 parts disodium edetate, 61.7 parts water, and appropriate amounts of citric acid / sodium citrate.
[0044] Formula 2: 1 part E isomer of the compound shown in formula (I), 2 parts white petrolatum, 7 parts cetostearyl alcohol, 3.5 parts macrogol cetostearyl ether, 10 parts medium-chain triglycerides, 3 parts monobisstearate glyceryl, 0.1 part dibutylhydroxytoluene, 0.15 parts ethylparaben, 1.5 parts polysorbate 80, 2 parts diethylene glycol monoethyl ether, 8 parts propylene glycol, 0.05 parts disodium edetate, 61.7 parts water, and appropriate amounts of citric acid / sodium citrate.
[0045] Formula 3: 4 parts of the E isomer of the compound shown in formula (I), 2 parts of white petrolatum, 7 parts of cetostearyl alcohol, 3.5 parts of macrogol cetostearyl ether, 10 parts of medium-chain triglycerides, 3 parts of glyceryl monobisstearate, 0.1 parts of dibutylhydroxytoluene, 0.15 parts of ethylparaben, 1.5 parts of polysorbate 80, 2 parts of diethylene glycol monoethyl ether, 8 parts of propylene glycol, 0.05 parts of disodium edetate, 58.7 parts of water, and appropriate amounts of citric acid / sodium citrate.
[0046] Formula 4: 0.5 parts of the E isomer of the compound shown in formula (I), 2 parts of white petrolatum, 7 parts of cetostearyl alcohol, 3.5 parts of macrogol cetostearyl ether, 10 parts of medium-chain triglycerides, 3 parts of monobisstearate glyceryl, 0.1 parts of dibutylhydroxytoluene, 0.15 parts of ethylparaben, 1.5 parts of polysorbate 80, 2 parts of diethylene glycol monoethyl ether, 8 parts of propylene glycol, 0.05 parts of disodium edetate, 62.2 parts of water, and appropriate amounts of citric acid / sodium citrate.
[0047] Formula 5: 2 parts of the E isomer of the compound shown in formula (I), 2 parts of white petrolatum, 7 parts of cetostearyl alcohol, 3.5 parts of macrogol cetostearyl ether, 10 parts of medium-chain triglycerides, 3 parts of monobisstearate glyceryl, 0.1 part of dibutylhydroxytoluene, 0.15 parts of ethylparaben, 1.5 parts of polysorbate 80, 2 parts of diethylene glycol monoethyl ether, 8 parts of propylene glycol, 0.05 parts of disodium edetate, 60.7 parts of water, and appropriate amounts of citric acid / sodium citrate.
[0048] Formula 6: 3 parts E isomer of the compound shown in formula (I), 2 parts white petrolatum, 7 parts cetostearyl alcohol, 3.5 parts macrogol cetostearyl ether, 10 parts medium-chain triglycerides, 3 parts monobisstearate glyceryl, 0.1 part dibutylhydroxytoluene, 0.15 parts ethylparaben, 1.5 parts polysorbate 80, 2 parts diethylene glycol monoethyl ether, 8 parts propylene glycol, 0.05 parts disodium edetate, 59.7 parts water, and appropriate amounts of citric acid / sodium citrate.
[0049] In some embodiments, the pharmaceutical composition may further contain a second active ingredient.
[0050] This disclosure is, This includes obtaining by mixing the aforementioned components. The present invention further provides a method for preparing the above-mentioned pharmaceutical composition.
[0051] In one embodiment, the preparation method is (A1) A step of mixing a chelating agent, a pH adjuster, and water, heating them, and obtaining an aqueous phase solution, (A2) A step of mixing an oil phase matrix, an emulsifier, a thickener, and optionally a preservative and antioxidant, heating and dissolving them to obtain an oil phase solution, (A3) A step of mixing the active ingredient, a humectant, and an optional penetration enhancer, heating and dissolving them to obtain a third-phase solution, (A4) The step of transferring the aqueous phase solution into the oil phase solution, emulsifying it, and cooling it down, (A5) The step of adding the third phase solution to the emulsion system of step (A4), emulsifying and cooling to obtain the pharmaceutical composition.
[0052] According to embodiments of this disclosure, the pH of the aqueous solution is 4 to 6.5, for example, 5 to 6.
[0053] According to embodiments of the present disclosure, in step (A1) or step (A2), the heating temperature is 60 to 90°C, for example, 70 to 80°C.
[0054] According to embodiments of this disclosure, the heating temperature described in step (A3) is 50 to 65°C, for example, 55 to 60°C.
[0055] According to embodiments of this disclosure, the temperature to be cooled in step (A4) is 50 to 65°C, for example, 55 to 60°C.
[0056] According to embodiments of this disclosure, the emulsification time described in step (A4) or step (A5) is 10 to 25 minutes, for example, 15 minutes or 20 minutes.
[0057] In another embodiment, the preparation method is: (B1) A step of mixing a chelating agent, a pH adjuster, and water, heating them, and obtaining an aqueous phase solution, (B2) A step of mixing an oil phase matrix, an emulsifier, a thickener, and optionally a preservative and antioxidant, heating and dissolving them to obtain an oil phase solution, (B3) A step of mixing the active ingredient, a humectant, and an optional penetration enhancer, heating and dissolving them to obtain a third-phase solution, (B4) The step of transferring the third phase solution into the oil phase solution, keeping it warm, and stirring, (B5) The step of adding the aqueous phase solution to the mixing system of step (B4), emulsifying and cooling, then emulsifying and cooling again to obtain the pharmaceutical composition.
[0058] According to embodiments of this disclosure, the pH of the aqueous solution is 4 to 6.5, for example, 5 to 6.
[0059] According to embodiments of the present disclosure, in step (B1) or step (B2), the heating temperature is 60 to 90°C, for example, 70 to 80°C.
[0060] According to embodiments of this disclosure, the heating temperature described in step (B3) is 50 to 65°C, for example, 55 to 60°C.
[0061] According to embodiments of the present disclosure, in step (B5), the time for the first emulsification is greater than the time for the second emulsification, for example, the time for the first emulsification is 10 to 25 minutes, for example, 15 minutes and 20 minutes.
[0062] According to embodiments of this disclosure, in step (B5), the first cooling reduces the temperature to 48-52°C.
[0063] In one embodiment, the preparation method is (C1) A step of mixing a chelating agent, a pH adjuster, and water, heating them, and obtaining an aqueous phase solution, (C2) A step of mixing the active ingredient, oil phase matrix, emulsifier, thickener, humectant, and optionally included preservatives, antioxidants, and penetration enhancers, heating and dissolving them to obtain an oil phase solution, (C3) The step of adding the oil phase solution to the aqueous phase solution, emulsifying it, and cooling it to obtain the pharmaceutical composition.
[0064] According to embodiments of this disclosure, the pH of the aqueous solution is 4 to 6.5.
[0065] According to embodiments of the present disclosure, in step (C1) or step (C2), the heating temperature is 60 to 90°C, for example, 70 to 80°C.
[0066] According to embodiments of this disclosure, the emulsification time described in step (C3) is 5 to 20 minutes, for example, 10 minutes or 15 minutes.
[0067] This disclosure further provides the use of the above-mentioned pharmaceutical composition in the preparation of a pharmaceutical formulation, preferably the pharmaceutical formulation being a cream.
[0068] This disclosure is, Preferably in the form of a cream, and comprising the above pharmaceutical composition, We will provide even more pharmaceutical formulations.
[0069] According to embodiments of the present disclosure, in the pharmaceutical formulation, the mass percentage of the active ingredient (i.e., at least one of the compound shown in formula (I) and its pharmaceutically acceptable salts) is 0.1 to 8%, for example, 0.5 to 5%, and exemplary, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 1.75%, 2%, 2.5%, 3%, 3.5%, or 4%.
[0070] According to embodiments of the present disclosure, the pharmaceutical composition or pharmaceutical preparation is used to treat atopic dermatitis and psoriasis, wherein the atopic dermatitis is preferably pediatric atopic dermatitis, for example, mild, moderate, severe, or refractory pediatric atopic dermatitis.
[0071] In another embodiment, the disclosure relates to the use of the above pharmaceutical composition in the preparation of a drug for treating and / or preventing atopic dermatitis and psoriasis, wherein the atopic dermatitis is preferably childhood atopic dermatitis, and more preferably mild, moderate, severe, or refractory childhood atopic dermatitis.
[0072] In another embodiment, the disclosure relates to the use of the above-mentioned pharmaceutical composition in the preparation of a drug for treating and / or preventing seborrheic dermatitis, wherein the seborrheic dermatitis is preferably seborrheic dermatitis.
[0073] In one embodiment, the route of administration of the pharmaceutical composition or the pharmaceutical preparation is local administration, or further, in combination with an oral preparation or other local administration preparation.
[0074] This disclosure further provides a method for treating and / or preventing atopic dermatitis, psoriasis and / or seborrheic dermatitis, wherein the pharmaceutical composition or pharmaceutical preparation is administered to a patient in an effective amount or therapeutically effective amount, wherein the atopic dermatitis is preferably pediatric atopic dermatitis and the seborrheic dermatitis is preferably seborrheic dermatitis.
[0075] Definitions and explanations of terms Unless otherwise specified, the definitions of terms used in the specification and claims of this application include definitions in practice, illustrative definitions, preferred definitions, definitions in tables, definitions of specific compounds in examples, etc., and can be combined and linked in any way. Such combinations and links should fall within the scope described in the specification of this application.
[0076] The terms “effective dose” or “therapeutic dose” mean an amount of the compound relating to this disclosure sufficient to achieve the expected use (including, but not limited to, the treatment of diseases as defined below). The therapeutic dose can vary depending on factors such as the expected use (in vitro or in vivo), the subject and disease state being treated (e.g., the subject’s weight and age), the severity of the disease state, and the method of administration, and can be readily determined by those skilled in the art. The specific dose will vary depending on factors such as the particular compound selected, the underlying method of administration, whether or not it is administered in combination with other compounds, the time schedule of administration, the tissue to which it is administered, and the physical delivery system on which it is carried.
[0077] The term "patient" means a person who needs to be prevented or treated for a disease associated with anaerobic bacteria, where the patient is a mammal, selected from, for example, rodents, cattle, pigs, dogs, cats, and primates, and in particular, humans.
[0078] The term "child" refers to patients aged 3 months or older, preferably those between 3 months and 18 years old, or between 3 months and 14 years old. [Effects of the Invention]
[0079] This disclosure provides a cream-type pharmaceutical composition / formulation in which the active ingredient is dispersed as homogeneous and uniform emulsion droplets and has good physical and chemical stability. The composition is applicable to atopic dermatitis and seborrheic dermatitis, and in particular to the treatment of pediatric atopic dermatitis and seborrheic dermatitis, and combines good safety and efficacy. [Brief explanation of the drawing]
[0080] [Figure 1] This is an external view of Example 1 after being left for one week. [Figure 2] This is a micrograph of Example 2. [Figure 3] This is a microscopic view of Example 3. [Figure 4] This is a microscopic view of Example 6. [Figure 5] This is a microscopic image of commercially available benzodiazepine cream. [Figure 6] This is a polarized light microscope image of commercially available benzodiazepine cream. [Figure 7] This is a comparative diagram of the skin retention amounts in the in vitro skin penetration test of Example 6 and the Comparative Example (commercially available benbitimod). Here, in the bar graphs for the Comparative Example and Example 6, the 1st, 2nd, 3rd, 4th, 5th, and 6th "bars" from left to right correspond to the experimental results of the 1st, 2nd, 3rd, 4th, 5th, and 6th trials of the Comparative Example or Example 6, respectively. [Figure 8] This is a comparison chart of the skin penetration amount in Example 6 and in an in vitro skin penetration test of commercially available benbitimod. [Figure 9] This shows the clinical effect of changes in the erythema index in the treatment of seborrheic dermatitis in Example 6. [Figure 10] This shows the clinical effect of changes in the desquamation index in the treatment of seborrheic dermatitis in Example 6. [Figure 11] This is a comparison chart of the skin retention amounts in the in vitro skin penetration test of Example 6 and Sample C. [Modes for carrying out the invention]
[0081] The technical proposals of this disclosure will be described in more detail below with reference to specific examples. It should be understood that the following examples are illustrative and should not be interpreted as limiting the scope of protection of this disclosure. All technologies realized based on the above-mentioned content of this disclosure fall within the scope of protection intended by this disclosure.
[0082] Unless otherwise specified, the raw materials and reagents used in the following examples are all commercially available or can be prepared by known methods. Commercially available benbitimod cream: Manufactured by Guangdong Zhonghao Pharmaceutical Co., Ltd., product name: Symbiox (registered trademark), benbitimod content: 1%.
[0083] Example 1: Initial Formulation By comparing the formulations disclosed in the instructions for commercially available benbitimod cream products, it is found to consist of an aqueous phase, an oil phase, an emulsifier, a solvent, and a preservative. See Table 1-1 below for specific formulations.
[0084] [Table 1]
[0085] Referring to Table 1-1, the composition of the initial formulation of this application is the formulation of Example 1 and Example 2, where the formulation of Example 1 is as shown in Table 1.
[0086] [Table 2]
[0087] The method for preparing the cream is as follows:
[0088] 1. Aqueous phase: Disodium edetate, sodium acetate, polysorbate 80, and purified water were placed in a beaker, heated to 70-80°C, stirred to dissolve, and the pH was adjusted to approximately 5-6 to obtain the aqueous phase.
[0089] 2. Oil phase: Light liquid paraffin, white petrolatum, PEG-7 stearate, octadecanol, ethylparaben, and dibutylhydroxytoluene were placed in a beaker, heated to 70-80°C, stirred, and dissolved to obtain the oil phase.
[0090] 3. Phase 3: Diethylene glycol monoethyl ether and propylene glycol were heated to 55-60°C, and the E isomer of the compound shown in formula (I) was added and dissolved to obtain the third phase.
[0091] 4. The aqueous phase was transferred to the oil phase, emulsified for 15 minutes, and then cooled to 55-60°C.
[0092] 5. The third phase was added to the emulsification system of step 4, emulsified for 15 minutes, and then cooled to obtain a cream.
[0093] Examples 2-4: Optimization of initial formulation The formulations for Examples 2-4 are shown in Table 2.
[0094] [Table 3]
[0095] The method for preparing the cream is as follows:
[0096] 1. Aqueous phase: Disodium edetate, sodium acetate without aqueous solution, and purified water were placed in a beaker, heated to 70-80°C, stirred to dissolve, and the pH was adjusted to approximately 5-6 to obtain the aqueous phase.
[0097] 2. Oil phase: Light liquid paraffin, white petrolatum, macrogol cetostearyl ether, cetostearyl alcohol, monobisstearate glyceryl, ethylparaben, polyoxyethylene (54) hydrogenated castor oil, and dibutylhydroxytoluene were placed in a beaker, heated to 70-80°C, stirred to dissolve, and the oil phase was obtained.
[0098] 3. Phase 3: Diethylene glycol monoethyl ether and propylene glycol were heated to 55-65°C, and the E isomer of the compound shown in formula (I) was added and dissolved to obtain the third phase.
[0099] 4. The third phase was transferred to the oil phase, kept warm, and stirred for 10 minutes.
[0100] 5. The mixture from step 4 was placed in the aqueous phase and emulsified for 10 minutes. After gradually cooling to 48-52°C, it was emulsified again for 5 minutes and then cooled to obtain the cream.
[0101] Example 5: Study of the physicochemical properties of Examples 1-4 Example 1: The cream was off-white in color, and under a microscope, the emulsion droplets appeared uniform. However, the cream had poor application properties and was hard. After being left for one week at 30°C / RH65%, the appearance of the cream changed significantly, from off-white to pale yellow. See Figure 1.
[0102] Example 2: This was a white cream that, under a microscope, showed the presence of large oily particles and uneven emulsion droplets, resulting in poor cream application. See Figure 2 for the relevant microscopic image.
[0103] Examples 3 and 4: By comparing Examples 2-4, the effect of white petrolatum in the formulation on product emulsion droplets can be examined. Microscopic observation shows that as the proportion of white petrolatum decreases, the particle size of the emulsion droplets in the sample decreases. For relevant microscopic images of Example 3, please refer to Figure 3.
[0104] Examples 5-7: Formulation optimization Based on the physicochemical results of Examples 1-4, the applicant decided to continue optimizing the formulation and, after considerable creative work, adjusted the types and contents of factors such as the oil phase matrix, thickeners, and pH adjusters. The final optimized formulation is shown in Table 3.
[0105] [Table 4]
[0106] The method for preparing the cream in Example 5 is as follows:
[0107] Step 1: Prepare the aqueous phase. Disodium edetate, sodium citrate, and citric acid were dissolved in purified water, heated to 70-80°C, kept warm, and the pH was adjusted to 4.5-6.5 to obtain the aqueous phase.
[0108] Step 2: Prepare the oil phase. The E isomer of the compound shown in formula (I), white petrolatum, cetostearyl alcohol, macrogol cetostearyl ether, monobisstearate glyceryl, medium-chain triglycerides, dibutylhydroxytoluene, polysorbate 80, propylene glycol, and ethylparaben were heated to 70-80°C to melt and then kept warm to obtain the oil phase.
[0109] Step 3: The oil phase was added to the aqueous phase, emulsified for 10 minutes, and then cooled to form a cream.
[0110] The preparation methods for the cream formulations in Examples 6 and 7 are as follows. Step 1: Prepare the aqueous phase by dissolving disodium edetate, sodium citrate, and citric acid in purified water, heating to 70-80°C, maintaining the temperature, adjusting the pH to 4.5-6.5, and obtaining the aqueous phase.
[0111] Step 2: Prepare the oil phase. The E isomer of the compound shown in formula (I), white petrolatum, cetostearyl alcohol, macrogol cetostearyl ether, monobisstearate glyceryl, medium-chain triglycerides, dibutylhydroxytoluene, polysorbate 80, diethylene glycol monoethyl ether, propylene glycol, and ethylparaben were heated to 70-80°C to melt and then kept warm.
[0112] Step 3: The oil phase was added to the aqueous phase, emulsified for 10 minutes, and then cooled to form a cream.
[0113] Example 8 Morphological Test The cream obtained in Example 6 was observed using a microscope, and it was found that the active ingredient was uniformly dispersed as emulsion droplets, and the particle size of the emulsion droplets was uniform, with all particle sizes being less than 5 μm. See Figure 4 for the microscopic image.
[0114] [Example 9] In vitro skin permeability test The effect of diethylene glycol monoethyl ether on skin retention was investigated using in vitro skin penetration testing (IVPT) as an indicator.
[0115] 1) Experimental Procedure In vitro skin penetration tests were performed on the formulations prepared in Examples 5 and 6 to evaluate the average retention amount of benbitimod in the epidermis and dermis. Pig skin (thickness 0.8-1.0 mm) was placed in a LOGAN System 918 vertical diffusion pool and tested at 1.77 cm 2 The surface area was exposed. The diffusion pool was connected to a multi-channel pump at a rotation speed of 600 rpm, and the receiving solution was PBS (phosphate buffer) with a pH of 7.4. Each pool was placed on a heated manifold to equalize the temperature and ensure that the skin surface temperature was 32°C (at least 30 minutes before administration). 10 mg / cm³ 2 Test samples were added at the specified dose. Receptacles were collected at 2, 4, 8, 20, and 24 hours, and the amount of active ingredient that penetrated the skin was measured. After 24 hours of sampling, the skin was wiped with a cotton swab to remove any residual sample that was not thought to have penetrated the skin, and the epidermis and dermis layers were separated by heating. The skin layers were cut, added to methanol, and the drug was extracted by sonication. The concentration of benbitimod was detected by high-performance liquid chromatography. The recovered drug concentrations were used to calculate the average retention amount of benbitimod in the skin.
[0116] 2) Test results In the formulation produced in Example 5, the average retention volume of benbitimod in the skin was 1.85 μg / cm³. 2 In the formulation produced in Example 6, the average retention volume of benbitimod in the skin was 2.91 μg / cm³. 2As can be seen from the skin penetration test results, increasing the amount of diethylene glycol monoethyl ether, which is a penetration enhancer, can significantly increase the total amount retained in the skin.
[0117] Example 10: Irritation Test Sixty healthy adult guinea pigs (30 females / 30 males) and 40 healthy young guinea pigs (20 females / 20 males) were selected and randomly divided into a negative control group, a positive control group, a low-dose adult animal test group (Example 6, 1%), a high-dose adult animal test group (Example 7, 4%), a low-dose young animal test group (Example 6, 1%), and a high-dose young animal test group (Example 7, 4%), based on sex and weight, using the software TOXSTAT2006. The negative control and positive control groups consisted of 10 guinea pigs each (5 females / 5 males), while the test groups consisted of 20 guinea pigs each (10 females / 10 males).
[0118] Hair removal: Before administration, first remove the hair from the animal using electric clippers, trimming the hair on the skin on both sides of the spine on the back, 3 x 3 cm on each side. 2 That is the case.
[0119] Sensitization: On days 0, 7, and 14, the test substance was administered at 0.2 g / animal (negative / positive control group: 0.2 mL / animal) to the left side of the alopecia area. Glass paper or filter paper was attached to the groove of the blank ointment patch, the test substance was placed on the glass paper or impregnated into the filter paper and attached to the administration site, and then sealed and secured with non-irritating medical tape. After approximately 6 hours, the blank ointment patch and filter paper were removed. Animals in the negative control group were administered 0.9% sodium chloride injection, and animals in the positive control group were administered 2% 2,4-dinitrochlorobenzene (80% ethanol, ultrasonically prepared). Animals in the low and high dose groups of the test substance were administered the formulations prepared in Example 6 and Example 7 at concentrations corresponding to the test substance low and high dose groups (benbitimod content was 1% and 4%, respectively).
[0120] Induction: On day 14 after the final sensitization, 0.2 g / guinea pig of the test substance (0.2 mL / guinea pig in the positive control group, prepared in a 0.2% 2,4-dinitrochlorobenzene and acetone solution; 0.2 mL / guinea pig in a 0.9% sodium chloride injection solution) was administered to the right side of the hair loss area in each group of guinea pigs, and the test substance was removed approximately 6 hours later.
[0121] Observation: Allergic reaction symptoms were observed and recorded 1 hour and 24 hours after sensitization, and 24 hours and 48 hours after induction.
[0122] The results showed that under these test conditions, after administering the formulations prepared in Examples 6 and 7 to guinea pigs multiple times, the Buehler test evaluation was negative, suggesting that skin sensitization remained absent even with increasing levels of the active ingredient, benbitimod.
[0123] Example 11: Stability Test The same amount of the cream from Example 6 was weighed and placed in aluminum tubes (sealed) to form a total of 6 groups. Each group was placed in an environment at room temperature and 40°C, and the physicochemical stability of the samples was observed and measured in the liquid phase at 0 days, 5 days at 40°C, 10 days at 40°C, 30 days at 40°C, 3 months at 40°C, and 6 months at 40°C. The specific results are shown in Table 4. The results showed that the cream from Example 6 did not oxidize or change color even after being stored for a long period of time, the active ingredients remained stable, it remained uniformly dispersed as emulsion droplets, there was no crystallization, the impurity content remained almost unchanged, and it exhibited excellent stability.
[0124] Liquid phase measurement method for impurities and their content: Octadecylsilane-bonded silica gel was used as the packing material, water as mobile phase A, and acetonitrile as mobile phase B. Gradient elution was performed, with the elution gradient being 0 min 80% A → 20~30 min 10% A → 32~40 min 80% A. The flow rate was 1.0 ml / min, the column temperature was 35°C, the detection wavelength was 220 nm, and the injection volume was 10 μl.
[0125] [Table 5]
[0126] Example 12: Comparison of the formulation produced in Example 6 with a commercially available benbitimod cream (comparative example). 1) Morphology: Under microscopic conditions, commercially available benbitimod cream showed heterogeneous emulsion droplets, large oily particles (see Figure 5), and solid crystals (see Figure 6) under a polarizing microscope.
[0127] 2) In vitro skin penetration test: The amount of benbitimod, the active ingredient, retained in the skin and the amount that penetrated it were examined.
[0128] The procedure for the in vitro skin penetration test followed the experimental procedure in Example 9. Six groups (n=6) were tested in parallel in the comparative example and the example. The test results are shown in Table 5 and Figures 7-8.
[0129] [Table 6]
[0130] From Table 5 and the average data on skin retention, it was found that in both Example 6 and the comparative example, the retention of benbitimod in the dermis was greater than the retention in the epidermis, and in Example 6, the retention of benbitimod in both the dermis and skin was greater than that of the control group. Furthermore, from Figure 7, it can be seen that the skin retention (dermis and epidermis) of Example 6 in each group was more uniform and stable than that of the comparative example in each group, and that the fluctuations in skin retention of Example 6 in each group were smaller. From the skin penetration data in Figure 8, it was found that the skin penetration of Example 6 was equivalent to that of the comparative example, and that Example 6 showed better parallelism, higher skin retention, and better efficacy.
[0131] Example 13 The cream prepared in Example 6 was partially applied to the skin of subjects suffering from atopic dermatitis (AD), ranging in age from 3 months to 14 years, and administered twice daily to the affected area. In some patients, a clear improvement was observed within 5 to 7 days, and the symptoms continued to be reduced within 1 month.
[0132] Example 14 In one prospective, randomized 8-week clinical trial, the cream formulation prepared in Example 6 (treatment group) was applied to the skin of subjects with seborrheic dermatitis, administered twice daily to the affected area. The control group used the matrix components of Example 6 without benbitimod, administered twice daily to the affected area. Significant improvement in the erythema index and desquamation index of seborrheic dermatitis was observed at week 2 and continued until week 8. At week 8, the erythema index decreased by 81.81% and the desquamation index decreased by 83.70% in the treatment group, while the erythema index decreased by 38.46% and the desquamation index decreased by 37.44% in the control group. Table 6 and Figures 9-10 demonstrate the clinical therapeutic effect of the AhR agonist benbitimod on treating patients with seborrheic dermatitis.
[0133] [Table 7]
[0134] Example 15 Based on the composition of Example 6, cream formulations were prepared according to the compositions of Samples 1-10 (the composition of Sample 9 was the same as in Example 6) shown in Table 7 below, and Samples 11-19 shown in Table 8 below, and the effect of the sample composition on the cream formulation product was evaluated.
[0135] The method for preparing the cream sample is as follows: Step 1: Prepare the aqueous phase. Disodium edetate, sodium citrate, and citric acid were dissolved in purified water, heated to 70-80°C, kept warm, and the pH was adjusted to 4.5-5.5 to obtain the aqueous phase.
[0136] Step 2: Prepare the oil phase. The E isomer of the compound shown in formula (I) and other components were mixed, heated to 70-80°C to melt, and then kept warm to obtain the oil phase.
[0137] Step 3: The oil phase was added to the aqueous phase, emulsified for 10 minutes, and then cooled to obtain a sample of the cream.
[0138] [Table 8]
[0139] [Table 9]
[0140] The results revealed the following:
[0141] In Table 7, oily material was present in the upper layer of Samples 1 and 2, preventing the dough from forming a uniform cream. Samples 3-10 were all able to prepare cream, but as the amount of white petrolatum decreased, the color of the cream changed from light pink to white. Microscopic observation of Samples 3 and 4 revealed that regular emulsion droplets were not formed, and small flake-like oily material was observed. Microscopic observation of Samples 5 and 6 showed that the oil phase could form circular emulsion droplets, and it was found that by controlling the amount of white petrolatum to 6% or less, samples with uniform emulsion droplets could be prepared.
[0142] Table 8 shows that the creams of Sample 11 and Sample 12 exhibited large, lumpy oil droplets under a microscope, while Sample 13 prepared a white cream with small emulsion droplets. This indicates that the emulsifier macrogol cetostearyl ether has good emulsifying ability over the oil phase matrix of medium-chain triglycerides and white petrolatum.
[0143] Samples 14-19 were able to prepare a white, uniform, and fine cream without oil-water separation. However, sample 14, which did not contain polysorbate 80, had uneven emulsion droplet size, and sample 15 had smaller, circular emulsion droplets, demonstrating that adding polysorbate 80 could improve the emulsion droplet size. Sample 18, which did not contain monobis-stearate glyceryl, also had uneven emulsion droplet size and exhibited a large oil droplet phenomenon, which was not observed in the other samples containing monobis-stearate glyceryl.
[0144] Furthermore, during the application process, it was observed that samples 13 and 15 containing a high proportion of polysorbate 80 or macrogol cetostearyl ether in the cream became whiter as they were applied. Viscosity detection revealed that creams with a high proportion of macrogol cetostearyl ether and a high proportion of monobisstearate glyceryl had a higher viscosity compared to creams with a lower proportion, indicating that macrogol cetostearyl ether and monobisstearate glyceryl have a certain thickening effect.
[0145] In summary, the preferred sample of the present invention has a moderate, uniform, and fine viscosity, and exhibits a good coating effect.
[0146] Example 16 Based on the composition of the cream formulation in Example 7, cream formulations were prepared according to the compositions of samples 20-22 shown in Table 9 below. The effect of the active ingredient content in each sample on the cream formulation product was evaluated, and the difference in active ingredient content between Example 7 and samples 20-22 was adjusted by the purified water content to maintain a constant content of other components.
[0147] [Table 10]
[0148] The method for preparing the cream sample is as follows:
[0149] Step 1: Prepare the aqueous phase. Disodium edetate, sodium citrate, and citric acid were dissolved in purified water, heated to 70-80°C, kept warm, and the pH was adjusted to 4.5-5.5 to obtain the aqueous phase.
[0150] Step 2: Prepare the oil phase. The E isomer of the compound shown in formula (I) and other components were mixed, heated to 70-80°C to melt, and then kept warm to obtain the oil phase.
[0151] Step 3: The oil phase was added to the aqueous phase, emulsified for 10 minutes, and then cooled to obtain a sample of the cream.
[0152] The results showed that off-white creams could be prepared with the compositions of Samples 20-22 and Example 7, with emulsion droplet diameters of less than 10 μm, indicating that the cream formulation of the present invention can be applied to active ingredients in different concentrations.
[0153] Example 17 Sample C was prepared with reference to the composition of Formulation 21 in Table 8 of the specification of Patent CN114042041A. The composition of the formulation was an oil phase (active ingredient, propylene glycol, diethylene glycol monoethyl ether, dibutylhydroxytoluene, benzoic acid, wax emulsion, medium-chain triglycerides, polysorbate 80, steareth 2, steareth 20) and an aqueous phase (disodium edetate, citric acid, sodium citrate, purified water). The preparation method involved mixing the oil phase components and heating to 70-80°C, continuing to mix until the active ingredient dissolved and the appearance became uniform; mixing the aqueous phase components and heating to 70-80°C, mixing until all substances were completely dissolved and the appearance of the aqueous phase became uniform; adding the oil phase to water, maintaining the temperature between 70-80°C, mixing for 5-10 minutes, and then cooling.
[0154] The in vitro skin penetration test procedure followed the experimental procedure in Example 9. The sample from Example 6 of this application was compared with sample C, and it was shown that, given the same active ingredient content, the intradermal retention amount of the cream sample from Example 6 of this application was higher than that of sample C (see Figure 11).
[0155] The above examples illustrate specific embodiments of the present invention. However, the scope of protection of the present invention is not limited to the above-described exemplary embodiments. Any modifications, equivalent substitutions, and improvements made by those skilled in the art within the spirit and principles of the present invention should all be included within the scope of the claims of the present invention.
[0156] This application claims priority over a prior application filed with the China National Intellectual Property Administration on November 2, 2023, patent application number 202311442719.6, with the title of invention "Pharmaceutical composition of phenol derivative with improved stability and its use." The entire text of the aforementioned prior application is incorporated herein by reference.
Claims
1. A pharmaceutical composition comprising an active ingredient selected from at least one compound shown in formula (I) and its pharmaceutically acceptable salts, a thickener, an emulsifier, a humectant, a chelating agent, a pH adjuster, an oil phase matrix, and water, 【Chemistry 1】 The oil phase matrix comprises one or two selected from petrolatum and possibly medium-chain triglycerides and paraffins. Preferably, the oil phase matrix is petrolatum and medium-chain triglycerides. Preferably, in the pharmaceutical composition, the amount of petrolatum (preferably white petrolatum) is 1 to 9 parts by weight, for example, 1 to 6 parts. Pharmaceutical composition.
2. The compound shown in formula (I) is either an E isomer or a Z isomer, and is preferably the E isomer shown in formula (I-1). 【Chemistry 2】 Preferably, the pharmaceutically acceptable salt is selected from the addition salt of the compound of formula (I) and a base. Preferably, in the pharmaceutical composition, only the compound shown in formula (I) is used as the active ingredient, and it is also preferable to use only the E isomer shown in formula (I-1) as the active ingredient. Preferably, in the pharmaceutical composition, the active ingredient exists as an emulsion droplet, and the diameter of the emulsion droplet is less than 10 μm. Preferably, in the pharmaceutical composition, the amount of the active ingredient is 0.1 to 8 parts by weight. The pharmaceutical composition according to claim 1.
3. The thickening agent is one or two selected from octadecanol and cetostearyl alcohol. Preferably, in the pharmaceutical composition, the amount of the thickening agent is 2 to 15 parts by weight. Preferably, the emulsifier is one or more selected from macrogol cetostearyl ether, monobis-glyceryl stearate, polyethylene glycol stearate, polyoxyethylene hydrogenated castor oil, and polysorbate 80, and preferably, the emulsifier contains at least macrogol cetostearyl ether and monobis-glyceryl stearate, for example, the emulsifier consists of macrogol cetostearyl ether and monobis-glyceryl stearate, or macrogol cetostearyl ether, monobis-glyceryl stearate, and polysorbate 80. Preferably, in the pharmaceutical composition, the amount of the emulsifier is 2 to 25 parts by weight, and if there are two types of emulsifiers, the weight ratio of the two types of emulsifiers is (1 to 3):(3 to 1), and if there are three types of emulsifiers, the weight ratio of the three types of emulsifiers is (1 to 3):(3 to 1):
1. Preferably, the humectant is one or more selected from propylene glycol, glycerin, and polyethylene glycol. Preferably, in the pharmaceutical composition, the amount of the humectant is 3 to 15 parts by weight. Preferably, the chelating agent is one or more selected from metal ion chelating agents such as ethylenediaminetetraacetic acid, sodium gluconate, nitrilotriacetic acid, tartaric acid, citric acid and its salts. Preferably, in the pharmaceutical composition, the amount of the chelating agent is 0.01 to 1 part by weight. Preferably, the pH adjusting agent is selected from pH buffers, and is preferably a pH buffer of an organic acid or its salt, for example, one or more selected from citrate / sodium citrate buffer, tartrate buffer, malic acid buffer, and acetic acid / sodium acetate buffer. Preferably, the oil phase matrix is one or more selected from petrolatum, medium-chain triglycerides, and paraffin. Preferably, in the pharmaceutical composition, the amount of the oil phase matrix is 5 to 25 parts by weight. Preferably, the water is purified water. Preferably, in the pharmaceutical composition, the amount of water is 40 to 65 parts by weight. The pharmaceutical composition according to claim 1 or 2.
4. The pharmaceutical composition further comprises an antioxidant, a preservative, and / or a penetration enhancer. Preferably, the antioxidant is one or two selected from propyl gallate and dibutylhydroxytoluene. Preferably, in the pharmaceutical composition, the amount of the antioxidant by weight is 0.01 to 0.2 parts. Preferably, the preservative is one or more selected from methylparaben, ethylparaben, and propylparaben. Preferably, in the pharmaceutical composition, the amount of the preservative is 0.01 to 0.3 parts by weight. Preferably, the penetration enhancer is one or more selected from diethylene glycol monoethyl ether, isopropyl myristate, isopropyl palmitate, menthol, polyethylene glycol glyceryl caprylate, N-methylpyrrolidone, propylene carbonate, and isosorbide dimethyl ether. Preferably, in the pharmaceutical composition, the amount of the penetration enhancer is 0.1 to 5 parts by weight. Preferably, the pH of the pharmaceutical composition is 4 to 6.
5. Preferably, the pharmaceutical composition further comprises a second active ingredient. A pharmaceutical composition according to any one of claims 1 to 3.
5. The pharmaceutical composition comprises, by weight, 0.1 to 8 parts of an active ingredient, 2 to 15 parts of a thickening agent, 2 to 25 parts of an emulsifier, 3 to 15 parts of a humectant, 0.01 to 1 part of a chelating agent, 0.01 to 0.2 parts of an antioxidant, 0.01 to 0.3 parts of a preservative, 0 to 5 parts of a penetration enhancer, 5 to 25 parts of an oil phase matrix, 40 to 65 parts of water, and a pH adjuster. The active ingredient is a compound of formula (I), and it is preferable that the E isomer shown in formula (I-1) be used as the active ingredient. Preferably, the pH of the pharmaceutical composition is 4 to 6.
5. Preferably, the pharmaceutical composition is, in parts by weight, The compound comprises 0.5 to 5 parts of the E isomer of the compound shown in formula (I), 5 to 10 parts of cetostearyl alcohol, 5 to 20 parts of emulsifier, 5 to 12 parts of propylene glycol, 0.05 to 0.5 parts of chelating agent, 0.01 to 0.2 parts of antioxidant, 0.01 to 0.3 parts of preservative, 0 to 5 parts of penetration enhancer, 8 to 20 parts of oil phase matrix, 40 to 65 parts of water, and an appropriate amount of pH adjuster. Preferably, the emulsifier consists of macrogol cetostearyl ether, monobisstearate glyceryl, and polysorbate 80 in a weight ratio of (1.5-3):(1.5-3):
1. Preferably, the oil phase matrix consists of white petrolatum and medium-chain triglycerides, with the amount of white petrolatum being 1 to 9 parts. A pharmaceutical composition according to any one of claims 1 to 4.
6. A method for preparing a pharmaceutical composition according to any one of claims 1 to 5, This includes obtaining by mixing the aforementioned components. Preparation method.
7. The aforementioned preparation method is (A1) A step of mixing a chelating agent, a pH adjuster, and water and heating to obtain an aqueous phase solution, (A2) A step of mixing an oil phase matrix, an emulsifier, a thickener, and optionally a preservative and antioxidant, heating and dissolving them to obtain an oil phase solution, (A3) A step of mixing the active ingredient, a humectant, and an optional penetration enhancer, heating and dissolving them to obtain a third-phase solution, (A4) The step of transferring the aqueous phase solution into the oil phase solution, emulsifying it, and cooling it down, Method 1 includes the step of (A5) adding the third phase solution to the emulsion system of step (A4), emulsifying and cooling to obtain the pharmaceutical composition, (B1) A step of mixing a chelating agent, a pH adjuster, and water and heating to obtain an aqueous phase solution, (B2) A step of mixing the oil phase matrix, emulsifier, thickener, and optional preservatives and antioxidants, heating and dissolving them to obtain an oil phase solution, (B3) A step of mixing the active ingredient, a humectant, and an optional penetration enhancer, heating and dissolving them to obtain a third-phase solution, (B4) The step of transferring the third phase solution into the oil phase solution, keeping it warm, and stirring, Method 2 includes the step of adding the aqueous solution to the mixed system of step (B4), emulsifying and cooling, then emulsifying and cooling again to obtain the pharmaceutical composition, and (C1) A step of mixing a chelating agent, a pH adjuster, and water and heating to obtain an aqueous phase solution, (C2) A step of mixing the active ingredient, oil phase matrix, emulsifier, thickener, humectant, and optionally included preservatives, antioxidants, and penetration enhancers, heating and dissolving them to obtain an oil phase solution, (C3) Add the oil phase solution to the aqueous phase solution, emulsify it, and cool it down to obtain the pharmaceutical composition; any one selected from method 3, The preparation method according to claim 6.
8. The pharmaceutical composition comprises the composition described in any one of claims 1 to 5, and is preferably a cream. Pharmaceutical preparations.
9. Use of the pharmaceutical composition according to any one of claims 1 to 5 in the preparation of a drug for treating and / or preventing atopic dermatitis and psoriasis, wherein the atopic dermatitis is preferably childhood atopic dermatitis, and more preferably mild, moderate, severe or refractory childhood atopic dermatitis. use.
10. Use of the pharmaceutical composition according to any one of claims 1 to 5 in the preparation of a drug for treating and / or preventing seborrheic dermatitis, wherein the seborrheic dermatitis is preferably seborrheic dermatitis. use.
11. A method comprising administering to a patient an effective amount or therapeutically effective amount of a pharmaceutical composition according to any one of claims 1 to 5 or a pharmaceutical preparation according to claim 8, wherein the atopic dermatitis is preferably pediatric atopic dermatitis, and the seborrheic dermatitis is preferably seborrheic dermatitis. A method for treating and / or preventing atopic dermatitis, psoriasis and / or seborrheic dermatitis, characterized by the above.
